Literature DB >> 33468990

AHA1 upregulates IDH1 and metabolic activity to promote growth and metastasis and predicts prognosis in osteosarcoma.

Diwei Zheng1, Weihai Liu2,3, Wenlin Xie4, Guanyu Huang2,3, Qiwei Jiang1, Yang Yang1, Jiarong Huang1, Zihao Xing1, Mengling Yuan1, Mengning Wei1, Yao Li1, Junqiang Yin5,6, Jingnan Shen7,8, Zhi Shi9.   

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Although activator of HSP90 ATPase activity 1 (AHA1) is reported to be a potential oncogene, its role in osteosarcoma progression remains largely unclear. Since metabolism reprogramming is involved in tumorigenesis and cancer metastasis, the relationship between AHA1 and cancer metabolism is unknown. In this study, we found that AHA1 is significantly overexpressed in osteosarcoma and related to the prognosis of osteosarcoma patients. AHA1 promotes the growth and metastasis of osteosarcoma both in vitro and in vivo. Mechanistically, AHA1 upregulates the metabolic activity to meet cellular bioenergetic needs in osteosarcoma. Notably, we identified that isocitrate dehydrogenase 1 (IDH1) is a novel client protein of Hsp90-AHA1. Furthermore, the IDH1 protein level was positively correlated with AHA1 in osteosarcoma. And IDH1 overexpression could partially reverse the effect of AHA1 knockdown on cell growth and migration of osteosarcoma. Moreover, high IDH1 level was also associated with poor prognosis of osteosarcoma patients. This study demonstrates that AHA1 positively regulates IDH1 and metabolic activity to promote osteosarcoma growth and metastasis, which provides novel prognostic biomarkers and promising therapeutic targets for osteosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33468990      PMCID: PMC7815748          DOI: 10.1038/s41392-020-00387-1

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  32 in total

1.  Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase.

Authors:  Dana M Gwinn; Alex G Lee; Marcela Briones-Martin-Del-Campo; Crystal S Conn; David R Simpson; Anna I Scott; Anthony Le; Tina M Cowan; Davide Ruggero; E Alejandro Sweet-Cordero
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

2.  Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.

Authors:  Benjamin Ory; Marc Baud'huin; Franck Verrecchia; Bénédicte Brounais-Le Royer; Thibaut Quillard; Jérôme Amiaud; Séverine Battaglia; Dominique Heymann; Francoise Redini; Francois Lamoureux
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

3.  Regulatory posttranslational modifications in hsp90 can be compensated by cochaperone aha1.

Authors:  Sonja Schmid; Thorsten Hugel
Journal:  Mol Cell       Date:  2011-03-18       Impact factor: 17.970

4.  A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.

Authors:  Arun Rajan; Ronan J Kelly; Jane B Trepel; Yeong Sang Kim; Sylvia V Alarcon; Shivaani Kummar; Martin Gutierrez; Sonja Crandon; Wadih M Zein; Lokesh Jain; Baskar Mannargudi; William D Figg; Brett E Houk; Michael Shnaidman; Nicoletta Brega; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

5.  MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1.

Authors:  Shilian Zhang; Yuehua Zhao; Lijie Wang
Journal:  Biochem Biophys Res Commun       Date:  2016-03-10       Impact factor: 3.575

6.  Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle.

Authors:  Jing Li; Klaus Richter; Jochen Reinstein; Johannes Buchner
Journal:  Nat Struct Mol Biol       Date:  2013-02-10       Impact factor: 15.369

7.  Genetic factors conferring metastasis in osteosarcoma.

Authors:  Vadim V Maximov; Rami I Aqeilan
Journal:  Future Oncol       Date:  2016-04-13       Impact factor: 3.404

8.  Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells.

Authors:  Masaki Mori; Toshiaki Hitora; Osamu Nakamura; Yoshiki Yamagami; Ryosuke Horie; Hideki Nishimura; Tetsuji Yamamoto
Journal:  Int J Oncol       Date:  2014-10-23       Impact factor: 5.650

Review 9.  The contributions of cancer cell metabolism to metastasis.

Authors:  Gloria Pascual; Diana Domínguez; Salvador Aznar Benitah
Journal:  Dis Model Mech       Date:  2018-05-03       Impact factor: 5.758

10.  c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells.

Authors:  Diana M Dunn; Mark R Woodford; Andrew W Truman; Sandra M Jensen; Jacqualyn Schulman; Tiffany Caza; Taylor C Remillard; David Loiselle; Donald Wolfgeher; Brian S J Blagg; Lucas Franco; Timothy A Haystead; Soumya Daturpalli; Matthias P Mayer; Jane B Trepel; Rhodri M L Morgan; Chrisostomos Prodromou; Stephen J Kron; Barry Panaretou; William G Stetler-Stevenson; Steve K Landas; Len Neckers; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Cell Rep       Date:  2015-07-30       Impact factor: 9.423

View more
  12 in total

1.  Graphene Oxide Nanoparticle-Loaded Ginsenoside Rg3 Improves Photodynamic Therapy in Inhibiting Malignant Progression and Stemness of Osteosarcoma.

Authors:  Shou-Liang Lu; Yan-Hua Wang; Guang-Fei Liu; Lu Wang; Yong Li; Zhi-Yuan Guo; Cai Cheng
Journal:  Front Mol Biosci       Date:  2021-04-22

2.  Cannabidiol promotes apoptosis of osteosarcoma cells in vitro and in vivo by activating the SP1-CBX2 axis.

Authors:  Fangxing Xu; Guiyuan Sun; Zhibin Peng; Jingsong Liu; Zecheng Li; Jinglong Yan
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

3.  AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.

Authors:  Chunyan Gu; Yajun Wang; Lulin Zhang; Li Qiao; Shanliang Sun; Miaomiao Shao; Xiaozhu Tang; Pinggang Ding; Chao Tang; Yuhao Cao; Yanyan Zhou; Mengjie Guo; Rongfang Wei; Nianguang Li; Yibei Xiao; Jinao Duan; Ye Yang
Journal:  J Exp Clin Cancer Res       Date:  2022-01-06

4.  HSP90 and Aha1 modulate microRNA maturation through promoting the folding of Dicer1.

Authors:  Xiaochuan Liu; Yen-Yu Yang; Yinsheng Wang
Journal:  Nucleic Acids Res       Date:  2022-06-23       Impact factor: 19.160

5.  IGF2BP1-regulated expression of ERRα is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells.

Authors:  Qing He; Peng Hao; Gang He; Hantao Mai; Wenzhou Liu; Weiqiong Zhang; Kelin Zhang; Guifang Zhong; Ruilian Guo; Changzhi Yu; Yang Li; Chipiu Wong; Qian Chen; Yantao Chen
Journal:  J Transl Med       Date:  2022-08-02       Impact factor: 8.440

6.  BA-GCA Net: Boundary-Aware Grid Contextual Attention Net in Osteosarcoma MRI Image Segmentation.

Authors:  Jia Wu; Zikang Liu; Fangfang Gou; Jun Zhu; Haoyu Tang; Xian Zhou; Wangping Xiong
Journal:  Comput Intell Neurosci       Date:  2022-07-30

Review 7.  Hsp90: From Cellular to Organismal Proteostasis.

Authors:  Milán Somogyvári; Saba Khatatneh; Csaba Sőti
Journal:  Cells       Date:  2022-08-10       Impact factor: 7.666

Review 8.  Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues.

Authors:  Morgane Lallier; Louise Marchandet; Brice Moukengue; Celine Charrier; Marc Baud'huin; Franck Verrecchia; Benjamin Ory; François Lamoureux
Journal:  Cells       Date:  2021-03-30       Impact factor: 6.600

9.  Inhibition of adult T-cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis.

Authors:  Tomonaga Ichikawa; Kazuhiro Sugamoto; Yasushi Matsuura; Hisato Kunitake; Kazuya Shimoda; Kazuhiro Morishita
Journal:  Cancer Sci       Date:  2022-02-13       Impact factor: 6.716

10.  Pleckstrin homology-like domain family A, member 3, a miR-19a-3p-regulated gene, suppresses tumor growth in osteosarcoma by downregulating the Akt pathway.

Authors:  Peng Wang; Yu Huang; Xin Xia; Jian Han; Lu Zhang; Wenzhi Zhao
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.